Institution
Linköping University
Education•Linköping, Sweden•
About: Linköping University is a education organization based out in Linköping, Sweden. It is known for research contribution in the topics: Population & Thin film. The organization has 15671 authors who have published 50013 publications receiving 1542189 citations.
Topics: Population, Thin film, Poison control, Health care, Photoluminescence
Papers published on a yearly basis
Papers
More filters
••
University of Bonn1, Hannover Medical School2, National Institute for Health Research3, Karolinska University Hospital4, University of North Dakota5, Mayo Clinic6, Oslo University Hospital7, University Hospital Heidelberg8, University of Helsinki9, University of Gothenburg10, Royal Free Hospital11, University Medical Center Groningen12, Katholieke Universiteit Leuven13, Charité14, Pierre-and-Marie-Curie University15, University of Hamburg16, Linköping University17, University College London18, University of Miami19, University of Alberta20, University of Oslo21, University of California, Davis22, University of Padua23, Medical University of Vienna24, California Pacific Medical Center25, Medical University of Warsaw26, Pomeranian Medical University27, Royal Adelaide Hospital28, University of Barcelona29, University of Zurich30, University of Thessaly31, University of Calgary32, University of Milan33, University of Tübingen34, Goethe University Frankfurt35, Saarland University36, Marche Polytechnic University37, John Radcliffe Hospital38, University of Oxford39, Arizona State University40, University of Toronto41, Toronto General Hospital42, Erasmus University Medical Center43
TL;DR: In an analysis of data from individual patients with PSC worldwide, significant variation in clinical course associated with age at diagnosis, sex, and ductal and IBD subtypes is found.
334 citations
••
First Faculty of Medicine, Charles University in Prague1, Medical University of Vienna2, Linköping University3, Institut Gustave Roussy4, University of Cologne5, University of Milan6, University of Lausanne7, Belfast Health and Social Care Trust8, University College Hospital9, Leiden University10, Athens State University11, Medical University of Graz12
TL;DR: The European Society of Gynaecological Oncology (ESGO), the European Society for Radiotherapy and Oncologists (ESTRO), and the European Pathology (EPSP) jointly developed clinically relevant and evidence-based guidelines in order to improve the quality of care for women with cervical cancer across Europe and worldwide.
Abstract: Background Despite significant advances in the screening, detection, and treatment of preinvasive cervical lesions, invasive cervical cancer is the fifth most common cancer in European women. There are large disparities in Europe and worldwide in the incidence, management, and mortality of cervical cancer. Objective The European Society of Gynaecological Oncology (ESGO), the European Society for Radiotherapy and Oncology (ESTRO), and the European Society of Pathology (ESP) jointly develop clinically relevant and evidence-based guidelines in order to improve the quality of care for women with cervical cancer across Europe and worldwide. Methods The ESGO/ESTRO/ESP nominated an international multidisciplinary development group consisting of practicing clinicians and researchers who have demonstrated leadership and expertise in the care and research of cervical cancer (23 experts across Europe). To ensure that the guidelines are evidence based, the current literature identified from a systematic search was reviewed and critically appraised. In the absence of any clear scientific evidence, judgment was based on the professional experience and consensus of the development group. The guidelines are thus based on the best available evidence and expert agreement. Prior to publication, the guidelines were reviewed by 159 international reviewers, selected through ESGO/ESTRO/ESP and including patient representatives. Results The guidelines cover comprehensively staging, management, and follow-up for patients with cervical cancer. Management includes fertility sparing treatment; stage T1a, T1b1/T2a1, clinically occult cervical cancer diagnosed after simple hysterectomy; early and locally advanced cervical cancer; primary distant metastatic disease; cervical cancer in pregnancy; and recurrent disease. Principles of radiotherapy and pathological evaluation are defined.
333 citations
••
TL;DR: The CANVAS Program (Canagliflozin Cardiovascular Assessment Study) as mentioned in this paper enrolled 10 142 participants with type 2 diabetes mellitus and high cardiovascular risk and reported the effects on heart failure and cardiovascular death overall, in those with and without a baseline history of heart failure.
Abstract: BACKGROUND : Canagliflozin is a sodium glucose cotransporter 2 inhibitor that reduces the risk of cardiovascular events. We report the effects on heart failure and cardiovascular death overall, in those with and without a baseline history of heart failure, and in other participant subgroups. METHODS : The CANVAS Program (Canagliflozin Cardiovascular Assessment Study) enrolled 10 142 participants with type 2 diabetes mellitus and high cardiovascular risk. Participants were randomly assigned to canagliflozin or placebo and followed for a mean of 188 weeks. The primary end point for these analyses was adjudicated cardiovascular death or hospitalized heart failure. RESULTS : Participants with a history of heart failure at baseline (14.4%) were more frequently women, white, and hypertensive and had a history of prior cardiovascular disease (all P P P interaction =0.021). The effects of canagliflozin compared with placebo on other cardiovascular outcomes and key safety outcomes were similar in participants with and without heart failure at baseline (all interaction P values >0.130), except for a possibly reduced absolute rate of events attributable to osmotic diuresis among those with a prior history of heart failure ( P =0.03). CONCLUSIONS : In patients with type 2 diabetes mellitus and an elevated risk of cardiovascular disease, canagliflozin reduced the risk of cardiovascular death or hospitalized heart failure across a broad range of different patient subgroups. Benefits may be greater in those with a history of heart failure at baseline. CLINICAL TRIAL REGISTRATION : URL: https://www.clinicaltrials.gov.
Unique identifiers: NCT01032629 and NCT01989754.
332 citations
••
TL;DR: In this paper, the authors investigate the potential of massive MIMO while addressing practical deployment issues to deal with the increased back/fronthauling overhead deriving from the signal co-processing.
Abstract: Since the first cellular networks were trialled in the 1970s, we have witnessed an incredible wireless revolution. From 1G to 4G, the massive traffic growth has been managed by a combination of wider bandwidths, refined radio interfaces, and network densification, namely increasing the number of antennas per site. Due its cost-efficiency, the latter has contributed the most. Massive MIMO (multiple-input multiple-output) is a key 5G technology that uses massive antenna arrays to provide a very high beamforming gain and spatially multiplexing of users and hence increases the spectral and energy efficiency (see references herein). It constitutes a centralized solution to densify a network, and its performance is limited by the inter-cell interference inherent in its cell-centric design. Conversely, ubiquitous cell-free Massive MIMO refers to a distributed Massive MIMO system implementing coherent user-centric transmission to overcome the inter-cell interference limitation in cellular networks and provide additional macro-diversity. These features, combined with the system scalability inherent in the Massive MIMO design, distinguish ubiquitous cell-free Massive MIMO from prior coordinated distributed wireless systems. In this article, we investigate the enormous potential of this promising technology while addressing practical deployment issues to deal with the increased back/front-hauling overhead deriving from the signal co-processing.
331 citations
••
TL;DR: This paper explores in this paper a set of notions of human dignity, which are introduced and characterized as a position on a value scale and further specified through its relations to the notions of right, respect and self-respect.
Abstract: As a part of a research project on Dignity and Older Europeans (Fifth Framework (Quality of Life) Programme) I explore in this paper a set of notions of human dignity. The general concept of dignity is introduced and characterized as a position on a value scale and it is further specified through its relations to the notions of right, respect and self-respect. I present four kinds of dignity and spell out their differences: the dignity of merit, the dignity of moral or existential stature, the dignity of identity and the universal human dignity (Menschenwurde). Menschenwurde pertains to all human beings to the same extent and cannot be lost as long as the persons exist. The dignity of merit depends on social rank and position. There are many species of this kind of dignity and it is very unevenly distributed among human beings. The dignity of merit exists in degrees and it can come and go. The dignity of moral stature is the result of the moral deeds of the subject; likewise it can be reduced or lost through his or her immoral deeds. This kind of dignity is tied to the idea of a dignified character and of dignity as a virtue. The dignity of moral stature is a dignity of degree and it is also unevenly distributed. The dignity of identity is tied to the integrity of the subject's body and mind, and in many instances, although not always, also dependent on the subject's self-image. This dignity can come and go as a result of the deeds of fellow human beings and also as a result of changes in the subject's body and mind.
331 citations
Authors
Showing all 15844 results
Name | H-index | Papers | Citations |
---|---|---|---|
Rui Zhang | 151 | 2625 | 107917 |
Jun Lu | 135 | 1526 | 99767 |
Jean-Luc Brédas | 134 | 1026 | 85803 |
Lars Wallentin | 124 | 767 | 61020 |
S. Shankar Sastry | 122 | 858 | 86155 |
Gerhard Andersson | 118 | 902 | 49159 |
Olle Inganäs | 113 | 627 | 50562 |
Antonio Facchetti | 111 | 602 | 51885 |
Ray H. Baughman | 110 | 616 | 60009 |
Michel W. Barsoum | 106 | 543 | 60539 |
Louis J. Ignarro | 106 | 335 | 46008 |
Per Björntorp | 105 | 386 | 40321 |
Jan Lubinski | 103 | 689 | 52120 |
Magnus Johannesson | 102 | 342 | 40776 |
Barbara Riegel | 101 | 507 | 77674 |